Pociredir
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Mar 1, 2026 → Jul 5, 2030
NCT ID
NCT07401823About Pociredir
Pociredir is a phase 2 stage product being developed by Fulcrum Therapeutics for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07401823. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07401823 | Phase 2 | Recruiting |
| NCT07431398 | Phase 1 | Recruiting |
Competing Products
20 competing products in Sickle Cell Disease